SEARCH:   Advanced

Blood, 15 December 2007, Vol. 110, No. 13, pp. 4385-4395. Prepublished online as a Blood First Edition Paper on August 28, 2007; DOI 10.1182/blood-2007-03-082404. This Article Full Text (PDF) Supplemental Tables All Versions of this Article: blood-2007-03-082404v1 110/13/4385    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Haase, D. Articles by Steidl, C. Search for Related Content PubMed PubMed Citation Articles by Haase, D. Articles by Steidl, C. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 29, 2007 Accepted July 19, 2007 New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients Detlef Haase*, Ulrich Germing, Julie Schanz, Michael Pfeilstocker, Thomas Nosslinger, Barbara Hildebrandt, Andrea Kundgen, Michael Lubbert, Regina Kunzmann, Aristoteles A.N. Giagounidis, Carlo Aul, Lorenz Trumper, Otto Krieger, Reinhard Stauder, Thomas H. Muller, Friedrich Wimazal, Peter Valent, Christa Fonatsch, and Christian Steidl Department of Hematology and Oncology, University of Gottingen, Gottingen, Germany Department of Hematology and Oncology, University of Dusseldorf, Dusseldorf, Germany 3rd Medical Department for Hematology and Oncology, and L. Boltzmann Institute for Leukemia Research and Hematology, Hanusch Hospital, Vienna, Austria Department of Hematology and Oncology, University of Freiburg, Freiburg, Germany Department of Hematology and Oncology, Johannes Hospital, Duisburg, Germany Department of Hematology and Oncology, Elisabethinen Hospital, Linz, Austria Department of Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria Institute of Biostatistics, University of Munich, Munich, Germany Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria * Corresponding author; email: haase.onkologie{at}med.uni-goettingen.de. We have generated a large, unique database that includes morphologic, cytogenetic, and follow-up data from 2124 patients with MDS at 4 institutions in Austria and 4 in Germany. Cytogenetic analyses were successfully performed in 2072 patients (97.6%), revealing clonal abnormalities in 1084 (52.3%). Numerical and structural chromosomal abnormalities were documented for each patient and subdivided further according to the number of additional abnormalities. The impact of the karyotype on the natural course of the disease was studied in 1286 patients treated with supportive care only. Median survival was 53.4 months for patients with normal karyotypes (n = 612) and 8.7 months for those with complex anomalies (n = 166). Thirteen rare abnormalities were identified with good [+1/+1q, t(1q), t(7q), 9q-, 12p-, chromosome 15 anomalies, t(17q), monosomy 21, trisomy 21, –X], intermediate (11q-, chromosome 19 anomalies), or poor [t(5q)] prognostic impact, respectively. For all World Health Organization (WHO) and French-American-British (FAB) classification system subtypes, the karyotype provided additional prognostic information. Our analyses offer new insights into the prognostic significance of rare chromosomal abnormalities and specific karyotypic combinations in MDS. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C. W. Choi, Y. J. Chung, C. Slape, and P. D. Aplan A NUP98-HOXD13 Fusion Gene Impairs Differentiation of B and T Lymphocytes and Leads to Expansion of Thymocytes with Partial TCRB Gene Rearrangement J. Immunol., November 15, 2009; 183(10): 6227 - 6235. [Abstract] [Full Text] [PDF] A. Tefferi and J. W. Vardiman Myelodysplastic Syndromes N. Engl. J. Med., November 5, 2009; 361(19): 1872 - 1885. [Full Text] [PDF] R. V. Tiu, L. P. Gondek, C. L. O'Keefe, J. Huh, M. A. Sekeres, P. Elson, M. A. McDevitt, X. F. Wang, M. J. Levis, J. E. Karp, et al. New Lesions Detected by Single Nucleotide Polymorphism Array-Based Chromosomal Analysis Have Important Clinical Impact in Acute Myeloid Leukemia J. Clin. Oncol., November 1, 2009; 27(31): 5219 - 5226. [Abstract] [Full Text] [PDF] O. Kosmider, V. Gelsi-Boyer, M. Cheok, S. Grabar, V. Della-Valle, F. Picard, F. Viguie, B. Quesnel, O. Beyne-Rauzy, E. Solary, et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs) Blood, October 8, 2009; 114(15): 3285 - 3291. [Abstract] [Full Text] [PDF] A. Czibere, I. Bruns, B. Junge, R. Singh, G. Kobbe, R. Haas, and U. Germing Low RPS14 expression is common in myelodysplastic syndromes without 5q- aberration and defines a subgroup of patients with prolonged survival Haematologica, October 1, 2009; 94(10): 1453 - 1455. [Abstract] [Full Text] [PDF] M. A. Sekeres and D. P. Steensma Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment Blood, September 24, 2009; 114(13): 2575 - 2580. [Abstract] [Full Text] [PDF] M. Cazzola Flow cytometry immunophenotyping for diagnosis of myelodysplastic syndrome Haematologica, August 1, 2009; 94(8): 1041 - 1043. [Full Text] [PDF] A. A. van de Loosdrecht, C. Alhan, M. C. Bene, M. G. Della Porta, A. M. Drager, J. Feuillard, P. Font, U. Germing, D. Haase, C. H. Homburg, et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes Haematologica, August 1, 2009; 94(8): 1124 - 1134. [Abstract] [Full Text] [PDF] R. M. Stone How I treat patients with myelodysplastic syndromes Blood, June 18, 2009; 113(25): 6296 - 6303. [Full Text] [PDF] L. Ades, S. Boehrer, T. Prebet, O. Beyne-Rauzy, L. Legros, C. Ravoet, F. Dreyfus, A. Stamatoullas, M. Pierre Chaury, J. Delaunay, et al. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study Blood, April 23, 2009; 113(17): 3947 - 3952. [Abstract] [Full Text] [PDF] G. Garcia-Manero Standard-of-care Approaches for Myelodysplastic Syndromes ASCO Educational Book, January 1, 2009; 2009(1): 408 - 412. [Abstract] [Full Text] [PDF] R. S. Komrokji and J. M. Bennett What Is "WHO"?: Myelodysplastic Syndrome Classification and Prognosis ASCO Educational Book, January 1, 2009; 2009(1): 413 - 419. [Abstract] [Full Text] [PDF] M. A. Sekeres, W. M. Schoonen, H. Kantarjian, A. List, J. Fryzek, R. Paquette, and J. P. Maciejewski Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys J Natl Cancer Inst, November 5, 2008; 100(21): 1542 - 1551. [Abstract] [Full Text] [PDF] B. L. Scott, D. A. Wells, M. R. Loken, D. Myerson, W. M. Leisenring, and H. J. Deeg Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome Blood, October 1, 2008; 112(7): 2681 - 2686. [Abstract] [Full Text] [PDF] J. P. Maciejewski and G. J. Mufti Whole genome scanning as a cytogenetic tool in hematologic malignancies Blood, August 15, 2008; 112(4): 965 - 974. [Abstract] [Full Text] [PDF] M. Mallo, L. Arenillas, B. Espinet, M. Salido, J. M{a} Hernandez, E. Lumbreras, M. del Rey, E. Arranz, S. Ramiro, P. Font, et al. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q- Haematologica, July 1, 2008; 93(7): 1001 - 1008. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020